Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer.

[1]  Olga V. Patterson,et al.  Using multiple sources of data for surveillance of postoperative venous thromboembolism among surgical patients treated in Department of Veterans Affairs hospitals, 2005-2010. , 2015, Thrombosis research.

[2]  Gary H Lyman,et al.  Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Rybin,et al.  Care of patients undergoing vascular surgery at safety net public hospitals is associated with higher cost but similar mortality to nonsafety net hospitals. , 2014, Journal of vascular surgery.

[4]  Dan J Stein,et al.  Venous thromboembolism in otolaryngology surgical inpatients receiving chemoprophylaxis , 2014, Head & neck.

[5]  D. McAneny,et al.  Reducing postoperative venous thromboembolism complications with a standardized risk-stratified prophylaxis protocol and mobilization program. , 2014, Journal of the American College of Surgeons.

[6]  J. Berlin,et al.  Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty , 2014, Vascular health and risk management.

[7]  E. Reed,et al.  Validation of a venous thromboembolism risk assessment model in gynecologic oncology. , 2012, Gynecologic oncology.

[8]  M. Menon,et al.  Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. , 2014, JAMA surgery.

[9]  A. Khorana,et al.  Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients. , 2013, Clinical lung cancer.

[10]  N. Sengupta,et al.  Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer’s Perspective , 2012, PharmacoEconomics.

[11]  Michael K Gould,et al.  Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[12]  Elie A Akl,et al.  Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .

[13]  M. Corriere,et al.  Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. , 2011, Journal of vascular surgery.

[14]  M. McCarter,et al.  Post-Discharge Venous Thromboembolism After Cancer Surgery: Extending the Case for Extended Prophylaxis , 2011, Annals of surgery.

[15]  J. Rubin,et al.  Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. , 2011, Journal of the American College of Surgeons.

[16]  M. Mandalà,et al.  Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  R. Pendleton,et al.  Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. , 2010, Thrombosis research.

[18]  R. Gurski,et al.  The Impact of Gastric Bypass on Gastroesophageal Reflux Disease in Patients With Morbid Obesity: A Prospective Study Based on the Montreal Consensus , 2010, Annals of surgery.

[19]  D. Campbell,et al.  A Validation Study of a Retrospective Venous Thromboembolism Risk Scoring Method , 2010, Annals of surgery.

[20]  M. Huo,et al.  Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review. , 2009, Clinical therapeutics.

[21]  Nancy Gordon,et al.  Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. , 2008, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[22]  Bengt I Eriksson,et al.  Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial , 2008, The Lancet.

[23]  B. Eriksson,et al.  Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. , 2008, The New England journal of medicine.

[24]  A. Kakkar.  Venous thromboembolism prophylaxis and treatment in patients with cancer. , 2008, Clinical advances in hematology & oncology : H&O.

[25]  Jay Lin,et al.  Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. , 2015, Journal of managed care pharmacy : JMCP.

[26]  L. Jørgensen,et al.  Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open‐label study , 2006, Journal of thrombosis and haemostasis : JTH.

[27]  G. Rozycki,et al.  Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group. , 2002, The Journal of trauma.

[28]  A. Cohen,et al.  Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. , 2002, The New England journal of medicine.

[29]  G. Raskob,et al.  Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty , 2001, Annals of Internal Medicine.

[30]  Janis Bormanis,et al.  Value of assessment of pretest probability of deep-vein thrombosis in clinical management , 1997, The Lancet.

[31]  T. Shields,et al.  General Thoracic Surgery , 1972 .